 |
| Merck's Gardasil |
Worries over Gardasil's safety are just one of the issues that have hampered uptake of Merck's ($MRK) best-selling vaccine for HPV. But now, a study published in JAMA says patients need not worry about an increased risk of deadly blood clots--a.k.a. venous thromboembolism, or VTE--in the period after vaccination. Researchers in Denmark examined a database of 1,613,798 women, finding that those who received the vaccine averaged 0.126 clots per person per year, compared with a rate of 0.159 clots per person per year in those who did not receive it. More